Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona Cancer Center, discusses the potential of biosimilars and challenges in the ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% ...

The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...

Number 4: In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes ...

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...

Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex ...

A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...